Global Uveitis Treatment Market - 2022-2029

Market Overview

Uveitis Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Uveitis is an inflammation of the middle layer of an eye (uvea), also known as the uveal tract. Auto-immune disorders, injuries, inflammatory disorders, infections, and surgeries are common causes of uveitis. Common symptoms of uveitis include eye pain, eye floaters, blurred vision, increased sensitivity to light and redness of the eye.

Market Dynamics

The major driving forces are the rising incidence of uveitis, the presence of grants and fellowships, growing research and development activities.

The growing research and development activities are fueling the global market growth.

An increasing number of clinical trials for eye inflammation treatment are being conducted globally, for instance, according to the clinical trials. Gov currently, five different clinical trials are actively working on intervention for Uveitis, such as a study to estimate the efficiency and safety of Abatacept for Birdshot uveitis as an immunosuppressive treatment sponsored by Universitaire Ziekenhuizen Leuven and estimated completion on January 1, 2023, a study on Tofacitinib for the treatment of inflammatory eye disease sponsored by Washington University School of Medicine, a study focused on the outcome with the hydrophobic and hydrophilic intraocular lens in patients with and without uveitis sponsored by Vastra Gotaland Region and estimated completion on December 2022 and a phase 4 study to test the hypothesis that infliximab is clinically useful for patients with refractory childhood uveitis sponsored by Xiaomin Zhang, Tianjin Medical University and predicted completion by December 2022. Furthermore, 35 more clinical studies are recruiting, indicating the global market's future growth.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global Uveitis Treatment market growth.

However, the high prices, the side effects associated with the medications, and the lack of knowledge regarding eye disorders are expected to restrain the market growth. Also, the side effects of medications like watery eyes and irritation will likely hamper the market growth.

Industry analysis.

The global uveitis treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

During the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of Uveitis Treatment. Furthermore, the socializing restriction made it difficult to get regular eye checkups, leaving most uveitis patients undetected, negatively impacting the global uveitis treatment market.

Segment Analysis

Corticosteroids are presumed to be prevailing throughout the forecast period (2022-2029)

The corticosteroid segment is expected to grow at a high rate since it is considered the mainstay treatment for patients with non-infectious uveitis. Corticosteroid drugs are very useful in minimizing inflammation. The FDA approved several corticosteroid eye drops available on the market. Ophthalmologists generally recommend eye drops, oral medications, or injections of corticosteroids. Corticosteroid implant is also increasingly gaining traction for people with chronic eye inflammation disorders. For instance, Retisert of Bausch+Lomb is the US's first FDA-approved surgical corticosteroid implant for treating non-infectious posterior uveitis. Many novel clinical trials are developing for uveitis. For instance, a phase 2 trial for the efficiency and safety of the Interleukin-17A inhibitor Izokibep (ABY-035) for treating a non-infectious intermediate, posterior or pan-uveitis (LINNAEA) sponsored by ACELYRIN Inc. and estimated to be complete by November 2022 and clinical study on Abatacept in Patients With Birdshot HLA A29 Uveitis: a phase II prospective 0pen label interventional proof-of-concept study sponsored by Universitaire Ziekenhuizen Leuven and estimated to be completed by January 1, 2023.

Geographical Analysis

The North American region is overshadowing the global uveitis treatment market.

North America dominated the Uveitis Treatment market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase of approximately 15 cases per 100,000 population annually or some 38,000 new cases annually. It is a significant cause of blindness, accounting for 10-15% of all blindness in the United States, costing approximately $242 million annually. Furthermore, the NIH states that Uveitis is very common in the geriatric population and as the American geriatric population is growing at a high rate is contributing to its dominance over the market. For instance, as per the estimation from the U.S. Census Bureau, more than 56 million American adults aged 65 and older in the United States account for about 16.9% of the nation's population. By 2030, when the last person from the boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults.

Competitive Landscape

Competitive Landscape

The major players operating in the global uveitis treatment market are Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd, AbbVie Inc., Eyegate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences, Inc., Clearside Biomedical, Inc., and Aldeyra Therapeutics, Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the uveitis treatment market globally. For instance, on May 8, 2020, AbbVie Inc. acquired Allergan plc. Also, on JUNE 2, 2022, Bausch + Lomb announced Launched Biotrue Hydration Plus, a multi-purpose solution.

Bausch + Lomb

Overview

Bausch + Lomb is a leading eye health products manufacturing company headquartered in Canada and was founded in 1853. It is among the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. Bausch + Lomb, on May 6, 2022, became a publicly traded company in 2021; around 21,000 employees were working for Bausch + Lomb.

Product Portfolio

Bausch + Lomb Company's uveitis product portfolio has XIPERE, VISUDYNE and RETISERT.

The global uveitis treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.